Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.40 |
| ▸ | PYGL | P06737 | 1/20 | 0.38 |
| ▸ | PYGM | P11217 | 1/20 | 0.38 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.37 |
| ▸ | APOL1 | O14791 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19359238 | 1.00 | CRBN (0.42) | CRBNDDB1GAATSHRMAP3K14 | |
| SCHEMBL19359454 | 1.00 | CRBN (0.42) | CRBNDDB1GAATSHRMAP3K14 | |
| SCHEMBL11132566 | 0.82 | GAA (0.42) | CRBNDDB1GAATSHRMAP3K14 | |
| SCHEMBL11720185 | 0.82 | GAA (0.42) | CRBNDDB1GAATSHRMAP3K14 | |
| SCHEMBL19359394 | 0.80 | CRBN (0.64) | CRBNDDB1IKZF3 | |
| SCHEMBL17336169 | 0.80 | CRBN (0.64) | CRBNDDB1IKZF3 | |
| SCHEMBL28659413 | 0.77 | APOL1 (0.40) | CRBNDDB1GAATSHRMAP3K14 | |
| SCHEMBL6600630 | 0.77 | APOL1 (0.40) | CRBNDDB1GAATSHRMAP3K14 | |
| SCHEMBL9366340 | 0.77 | CRBN (0.73) | CRBNDDB1GAAPYGLPYGM | |
| SCHEMBL473720 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165095-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2024-05-23 | — | — | US | disclosed |
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20220362229-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-11-17 | — | — | US | disclosed |
| US-11395820-B2 | Small molecules against cereblon to enhance effector t cell function | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-11345714-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210177825-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-06-17 | — | — | US | disclosed |
| EP-3820532-A2 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | H. Lee Moffitt Cancer Center & Research Institute, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20210139500-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-10889593-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190322683-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10336771-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3429996-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. Lee Moffitt Cancer Center And Research Institute, Inc. (US) | 2019-01-23 | — | — | EP | disclosed |
| US-20180298027-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2018-10-18 | — | — | US | disclosed |
| US-10040804-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | Bio TheryX, Inc. | 2018-06-21 | — | — | US | disclosed |
| WO-2017161119-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | CRBN, CD4, CD74 | CRBN 1/4885DDB1 1404/4885GAA 2326/4885 |
| US-20220362229-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | CRBN, CD4, CD74 | CRBN 1/4885DDB1 1404/4885GAA 2326/4885 |
| US-11345714-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | CRBN 1160/4885DDB1 2309/4885GAA 2868/4885 |
| US-20210139500-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, CKS2 | CRBN 1205/4885DDB1 2584/4885GAA 2622/4885 |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | CRBN 1160/4885DDB1 2309/4885GAA 2868/4885 |
| US-10336771-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | CRBN 1160/4885DDB1 2309/4885GAA 2868/4885 |
| US-11395820-B2 | Small molecules against cereblon to enhance effector t cell function | CD4, GZMB, CRBN | CRBN 3/4885DDB1 2798/4885GAA 1485/4885 |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | CRBN 2/4885DDB1 3336/4885GAA 2081/4885 |
| US-20210177825-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, GZMB, CRBN | CRBN 3/4885DDB1 2798/4885GAA 1485/4885 |
| US-20180298027-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | CRBN 1160/4885DDB1 2309/4885GAA 2868/4885 |
| US-20240165095-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | CRBN, CD4, CD74 | CRBN 1/4885DDB1 1404/4885GAA 2326/4885 |
| US-10889593-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | CRBN 1160/4885DDB1 2309/4885GAA 2868/4885 |
| US-10040804-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | CRBN 1160/4885DDB1 2309/4885GAA 2868/4885 |
| US-20190322683-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | CRBN 1160/4885DDB1 2309/4885GAA 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.